3-(3-chloropropoxy)-4-methoxybenzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-chloropropoxy)-4-methoxybenzoic acid
• 化学式: C₁₁H₁₃ClO₄
• 分子量: 244.675
• InChiKey: ACGIGZZCTAJWJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-chloropropoxy)-4-methoxybenzoic acid 在 氯化亚砜 、 硝酸 、 乙酸酐 、 铁粉 、 溶剂黄146 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 、 异丙醇 、 甲苯 为溶剂， 生成 吉非替尼中间体B
  参考文献：
  名称：

  Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors

  摘要：

  We report herein the design and synthesis of novel azaspirocycle or azetidine substituted 4-anilinoquinazoline derivatives. The EGFR inhibitory activities and in vitro antitumor potency of these newly synthesized compounds against two lung cancer cell lines HCC827 and A549 were evaluated. Most of the target compounds possess good inhibitory potency. In particular, compounds 21g with 2-oxa-6-azaspiro[3.4] octane substituent was found to possess higher EGFR inhibitory activities and similar antitumor potency comparing to the lead compound gefitinib with improved water solubility. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.049
• 作为产物：
  描述：

  methyl 3-(3-chloropropoxy)-4-methoxybenzoate 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 以95.8%的产率得到3-(3-chloropropoxy)-4-methoxybenzoic acid
  参考文献：
  名称：

  PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE

  摘要：

  公开号：

  EP1477481B1

文献信息

• [EN] COMPLEMENT MODULATORS AND RELATED METHODS<br/>[FR] MODULATEURS DU COMPLÉMENT ET PROCÉDÉS ASSOCIÉS
  申请人：RA PHARMACEUTICALS INC

  公开号：WO2020205501A1

  公开（公告）日：2020-10-08

  The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.

  本公开涉及与补体成分相互作用的化合物和组合物。一些化合物抑制补体活性。包括作为C5抑制剂化合物的小分子化合物和组合物。提供了抑制补体活性的方法以及利用C5抑制剂化合物和组合物治疗与补体相关症状的方法。
• [EN] NEW MACROLIDES AND THEIR USE<br/>[FR] NOUVEAUX MACROLIDES ET LEUR UTILISATION
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2009106419A1

  公开（公告）日：2009-09-03

  The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

  本发明涉及公式(I)的大环内酯化合物，以及所述化合物作为药物的应用，特别是用于治疗或预防炎性和过敏性疾病，包含所述化合物的药物组合物，以及它们的制备过程。本发明特别涉及主要通过抑制磷酸二酯酶4（PDE4）介导抗炎活性的大环内酯化合物，这使得它们可用于治疗和/或预防诸如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、特应性皮炎、炎症性肠病或增殖性疾病，例如癌症等炎性和过敏性疾病。
• Process for producing quinazolin-4-one derivative
  申请人：Nishino Shigeyoshi

  公开号：US20050080262A1

  公开（公告）日：2005-04-14

  A process for producing a quinazolin-4-one compound having the formula: [wherein R 1 , R 2 , R 3 and R 4 each represents a group not participating in the below-mentioned reaction, and R 1 , R 2 , R 3 and R 4 can be combined together to form a ring] which comprises reacting an anthranilic acid derivative having the formula: [wherein R 5 is a hydrogen atom or a hydrocarbyl group] with a formic acid derivative in the presence of an ammonium carboxylate.

  一种生产具有以下公式的喹唑啉-4-酮化合物的方法：[其中R1，R2，R3和R4各代表不参与下述反应的基团，并且R1，R2，R3和R4可以组合在一起形成一个环]，包括在铵羧酸存在下，将具有以下公式的蒽酰氨衍生物与甲酸衍生物反应：[其中R5是氢原子或烃基]。
• Synthesis and Spectroscopic Characterisation of Novel Rofumilast Analogues
  作者：Gangchun Sun、Yuhui Si、Ge Song、Wenpeng Mai、Zhicheng Li

  DOI：10.3184/174751913x13782291519608

  日期：2013.10

  A series of new N-heterocyclic or phenoxy substituted roflumilast analogues have been designed and synthesised. N-heterocyclic or phenoxy substituted benzaldehydes were first prepared from 3-hydroxy-4-methoxybenzaldehbyde and 1-bromo-3-chloropropane by an alkylation reaction. The roflumilast analogues were then obtained by oxidation, acylation, amidation and alkylation reactions. These compounds were characterised by H-1 NMR, IR, ESI-MS and elemental analyses.
• NEW MACROLIDES AND THEIR USE
  申请人：Basilea Pharmaceutica AG

  公开号：EP2464651B1

  公开（公告）日：2016-04-20